Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension Study
Marc Ferrante, Brian G Feagan, Julián Panés, Filip Baert, Edouard Louis, Olivier Dewit, Arthur Kaser, W Rachel Duan, Yinuo Pang, Wan-Ju Lee, Dawn Gustafson, Xiaomei Liao, Kori Wallace, Jasmina Kalabic, Geert R D'Haens, Marc Ferrante, Brian G Feagan, Julián Panés, Filip Baert, Edouard Louis, Olivier Dewit, Arthur Kaser, W Rachel Duan, Yinuo Pang, Wan-Ju Lee, Dawn Gustafson, Xiaomei Liao, Kori Wallace, Jasmina Kalabic, Geert R D'Haens
Abstract
Background and aims: Risankizumab, an interleukin-23 antibody, demonstrated efficacy and acceptable safety in a phase 2 study of patients with moderate-to-severe refractory Crohn's disease. This open-label extension investigated the long-term safety, pharmacokinetics, immunogenicity and efficacy of risankizumab in responders to risankizumab in the parent phase 2 study.
Methods: Enrolled patients had achieved clinical response [decrease in Crohn's Disease Activity Index from baseline ≥100] without clinical remission [Crohn's Disease Activity Index <150] at Week 26, or clinical response and/or remission at Week 52 in the parent phase 2 study and received open-label subcutaneous risankizumab 180 mg every 8 weeks.
Results: Sixty-five patients were enrolled, including four who had lost response in the parent study and were first reinduced with risankizumab 600 mg every 4 weeks [three infusions]. Patients received risankizumab for a median of 33 months [total: 167.0 patient-years]. The rate of serious adverse events was 24.6 events/100 patient-years; the majority were gastrointestinal in nature. Rates of serious infections, opportunistic infections and fungal infections were 4.2, 1.8, and 6.6 events/100 patient-years, respectively. No deaths, malignancies, adjudicated major adverse cardiovascular events, latent/active tuberculosis or herpes zoster were reported. Treatment-emergent anti-drug antibodies developed in eight patients [12.3%]; none were neutralizing. Efficacy outcomes were maintained during the study, including the proportions of patients [observed analysis] with clinical remission [>71%] and endoscopic remission [>42%].
Conclusions: Long-term maintenance treatment with subcutaneous risankizumab 180 mg every 8 weeks was well tolerated by patients with Crohn's disease, with no new safety signals. Clinical trial registration number: NCT02513459.
Keywords: Crohn’s disease; long-term safety; open-label extension.
© The Author(s) 2021. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation.
Figures
References
- Gomollón F, Dignass A, Annese V, et al. ; ECCO. 3rd European Evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 1: diagnosis and medical management. J Crohns Colitis 2017;11:3–25.
- Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG clinical guideline: management of Crohn’s disease in adults. Am J Gastroenterol 2018;113:481–517.
- Ng SC, Shi HY, Hamidi N, et al. . Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2017;390:2769–78.
- Ng SC, Tang W, Ching JY, et al. . Incidence and phenotype of inflammatory bowel disease based on results from the Asia-Pacific Crohn’s and colitis epidemiology study. Gastroenterology 2013;145:158–65.e2.
- Torres J, Bonovas S, Doherty G, et al. . ECCO guidelines on therapeutics in Crohn’s disease: medical treatment. J Crohns Colitis 2020;14:4–22.
- AbbVie. Skyrizi (risankizumab) [package insert]. European Medicines Agency website. July 13, 2020. . Accessed November 11, 2020.
- AbbVie. Skyrizi (risankizumab) [package insert]. U.S. Food and Drug Administration website. July 13, 2020. . Accessed November 11, 2020.
- Feagan BG, Sandborn WJ, D’Haens G, et al. . Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn’s disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet 2017;389:1699–709.
- Feagan BG, Panés J, Ferrante M, et al. . Risankizumab in patients with moderate to severe Crohn’s disease: an open-label extension study. Lancet Gastroenterol Hepatol 2018;3:671–80.
- Suleiman AA, Khatri A, Minocha M, Othman AA. Population pharmacokinetics of the interleukin-23 inhibitor risankizumab in subjects with psoriasis and Crohn’s disease: analyses of phase I and II trials. Clin Pharmacokinet 2019;58:375–87.
- Gordon KB, Strober B, Lebwohl M, et al. . Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet 2018;392:650–61.
- Reich K, Gooderham M, Thaçi D, et al. . Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. Lancet 2019;394:576–86.
- Mease PJ, Kellner H, Morita A, et al. . OP0307 Efficacy and safety of risankizumab, a selective il-23p19 inhibitor, in patients with active psoriatic arthritis over 24 weeks: results from a phase 2 trial. Ann Rheum Dis 2018;77:200–1.
- Feagan BG, Sandborn WJ, Gasink C, et al. ; UNITI–IM-UNITI Study Group. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 2016;375:1946–60.
- Sandborn WJ, Rutgeerts P, Gasink C, et al. . Long-term efficacy and safety of ustekinumab for Crohn’s disease through the second year of therapy. Aliment Pharmacol Ther 2018;48:65–77.
- Ghosh S, Gensler LS, Yang Z, et al. . Ustekinumab safety in psoriasis, psoriatic arthritis, and Crohn’s disease: an integrated analysis of phase II/III clinical development programs. Drug Saf 2019;42:751–68.
- Khatri A, Suleiman AA, Polepally AR, Othman AA. Exposure–response relationships for efficacy and safety of risankizumab in phase II and III trials in psoriasis patients. Clin Pharmacol Ther 2020;107:378–87.
- Pang Y, Khatri A, Suleiman AA, Othman AA. Clinical pharmacokinetics and pharmacodynamics of risankizumab in psoriasis patients. Clin Pharmacokinet 2020;59:311–26.
Source: PubMed